Light-induced retinal ganglion cell damage in vivo involves Dexras1.
OBJECTIVE
Light-induced retinal degeneration is a vision-threatening retinal disease. Light can damage not only photoreceptor cells but also retinal ganglion cells (RGCs). This study was aimed to observe the spatiotemporal expression of dexamethasone-induced Ras protein 1 (Dexras1) and document the effect of Dexras1 on RGC damage after light exposure.


METHODS
Adult Sprague-Dawley rats were exposed to bright white light for 2 h. Reverse transcriptase-PCR (RT-PCR) and western blot analysis were used to analyze mRNA and protein expression of Dexras1. The spatial distribution of Dexras1 and outer nuclear layer (ONL) thickness were evaluated by immunohistochemistry. Immunoﬂuorescence was performed to observe the colocalization of Dexras1. In addition, cell apoptosis in this model was measured using terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL). Finally, the effect of systemic administration of nitric oxide synthase (NOS) inhibitor on the retina was investigated by western blot analysis and immunoﬂuorescence.


RESULTS
Dexras1 expression increased at 6 h and reached the peak at 1 day, gradually recovering to the baseline level at 7 days after light exposure. Dexras1 immunoreactivity was detected in RGCs and colabeled with cleaved caspase-3 after light exposure, whereas cleaved caspase-3 immunoreactivity was undetectable in the ONL. However, immunohistochemistry demonstrated that the ONL thickness decreased after light exposure and TUNEL revealed that photoreceptor cell apoptosis also occurred. In addition, the ternary complex of Dexras1, neuronal NOS (nNOS), and the C-terminal PSD95/DLG/ZO-1 ligand of nNOS was observed in RGCs. Administration of NOS inhibitor decreased the expression of cleaved caspase-3 and Dexras1.


CONCLUSIONS
Exposure to light caused the transient high expression of Dexras1, which was colabeled with apoptotic marker, nNOS, and the C-terminal PSD95/DLG/ZO-1 ligand of nNOS in RGCs. Administration of the NOS inhibitor prevented RGC apoptosis by decreasing cleaved caspase-3 and Dexras1 expression. Dexras1-mediated RGC damage appears to act through activation of nNOS in this model.
Department of Ophthalmology, the Affiliated Hospital of Nantong University, Medical College, Nantong University, Nantong, China. amsang@yahoo.cn
Aimin
A
Sang
Yanyan
Y
Cheng
Hong
H
Lu
Doudou
D
Chen
Ruifang
R
Gao
Aiguo
A
Shen
D000818:Animals; D017209:Apoptosis; D053148:Caspase 3 / Q000378:metabolism; D005260:Female; D007274:Injections, Intraperitoneal; D008027:Light; D008297:Male; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D017434:Protein Structure, Tertiary; D051381:Rats; D017207:Rats, Sprague-Dawley; D012160:Retina / Q000473:pathology; D012165:Retinal Ganglion Cells / Q000166:cytology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D018631:ras Proteins / Q000235:genetics*
C528215:Rasd1 protein, rat; D019001:Nitric Oxide Synthase; D053148:Caspase 3; D018631:ras Proteins
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3559-67
18450590
J Clin Invest. 1997 Nov 15;100(10):2417-23
9366554
Mol Vis. 2007 Feb 11;14:334-44
18334950
Clin Chem Lab Med. 2001 Apr;39(4):299-307
11388652
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2697-705
10509668
Nature. 1993 Aug 12;364(6438):626-32
8394509
J Neurochem. 2008 Jun;105(5):2013-28
18315568
J Biol Chem. 2001 Jun 22;276(25):23000-8
11278285
Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1900-5
17389526
J Chem Neuroanat. 2008 Jan;35(1):85-93
17768032
Neuron. 2006 Aug 17;51(4):431-40
16908409
Invest Ophthalmol. 1966 Oct;5(5):450-73
5929286
Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3511-21
12407163
Prog Retin Eye Res. 2005 Mar;24(2):275-306
15610977
J Photochem Photobiol B. 2001 Nov 15;64(2-3):144-61
11744401
J Clin Invest. 1997 Nov 1;100(9):2146-52
9410890
Free Radic Biol Med. 2002 Dec 1;33(11):1440-50
12446201
Mol Vis. 2008 Apr 25;14:782-806
18483561
Ophthalmologe. 2010 Jan;107(1):22-9
19499229
Cell Mol Neurobiol. 2008 May;28(3):371-88
18219571
J Pharmacol Sci. 2004 Jan;94(1):77-80
14745122
J Cell Biol. 1998 Feb 9;140(3):637-45
9456323
Neurotoxicology. 2005 Oct;26(5):935-41
16126273
Neuron. 2000 Oct;28(1):183-93
11086993
Graefes Arch Clin Exp Ophthalmol. 2001 Oct;239(10):794-800
11760043
Prog Retin Eye Res. 2010 Mar;29(2):113-34
19951742
Neuron. 1998 Jan;20(1):115-24
9459447
Vision Res. 2007 Sep;47(21):2732-40
17825345
J Biol Chem. 1998 Dec 18;273(51):34272-7
9852091
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5699-707
18055822
Mol Ther. 2010 Nov;18(11):1917-26
20700110
Ophthalmologica. 2002 Nov-Dec;216(6):463-6
12569943
Vision Res. 1996 Sep;36(18):2979-94
8917798
Neurosci Lett. 2004 Sep 2;367(2):205-9
15331154
FEBS Lett. 1999 Jun 25;453(3):361-4
10405176
Exp Eye Res. 2004 Aug;79(2):287-93
15325575
Nat Biotechnol. 1999 Sep;17(9):878-83
10471929
J Neurosci. 1998 Feb 1;18(3):923-31
9437014
Neurochem Int. 2010 Oct;57(3):278-87
20558223
Trends Neurosci. 2002 Nov;25(11):571-7
12392932